Oracle Acquires Phase Forward, Diax Collects Up to $12M from Paul Capital, Agios Gets $130M from Celgene, & More Boston-Area Deals News
(Page 2 of 2)
existing investors LaunchCapital and Nickelodeon and Oxygen Media founder Gerry Laybourne. Daily Grommet also attracted new investors Jean Hammond of Hub Angels and Launchpad Venture Group, John Landry of Lead Dog Ventures, Nancy Peretsman, and Jill Preotle of Boston Golden Seeds.
—Phase Forward, a Waltham, MA-based maker of software for managing clinical trial data, will be acquired by database software giant Oracle (NASDAQ: ORCL) for $17 a share, or a total of $685 million, the companies announced Friday. The deal is still subject to shareholder approval, but represents a roughly 30 percent increase over Phase Forward’s closing stock price on Thursday of $13.08.
—Enterprise communication management software provider Tangoe filed for an initial public offering worth $75 million. Deutsche Bank Securities and Thomas Weisel Partners will act as joint book-runners for the Orange, CT-based company’s deal.
—Holden, MA-based topical drug developer Hygeia Therapeutics announced that it closed a $1 million Series A round, which will go toward testing for its topical synthetic estrogen treatment, and developing a topical anti-androgen drug.
—Dyax (NASDAQ: DYAX), a Cambridge drug developer, announced a deal worth up to $12 million with Paul Capital Healthcare, which will get the rights to royalties and fees from the sales of Dyax’s hemophilia treatment. Paul Capital will pay $10 million upfront and up to another $2 million in milestone payments related to the sale of the drug, which Pfizer (NYSE: PFE) is commercializing.